Please use this identifier to cite or link to this item:
Title: Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
Authors: Moreso, Francesc
Crespo, Marta
Ruiz, Juan C
Torres, Armando
Gutierrez-Dalmau, Alex
Osuna, Antonio
Perelló, Manel
Pascual, Julio
Torres, Irina B
Redondo-Pachón, Dolores
Rodrigo, Emilio
Lopez-Hoyos, Marcos
Seron, Daniel
Keywords: clinical research/practice;clinical trial;kidney (allograft) function/dysfunction;kidney transplantation/nephrology;pathology/histopathology;rejection: antibody-mediated (ABMR)
metadata.dc.subject.mesh: Adult
Chronic Disease
Double-Blind Method
Follow-Up Studies
Glomerular Filtration Rate
Graft Rejection
Graft Survival
HLA Antigens
Immunoglobulins, Intravenous
Immunologic Factors
Kidney Failure, Chronic
Kidney Function Tests
Kidney Transplantation
Middle Aged
Postoperative Complications
Prospective Studies
Risk Factors
Tissue Donors
Issue Date: 24-Oct-2017
Abstract: There are no approved treatments for chronic antibody mediated rejection (ABMR). We conducted a multicenter, prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate efficacy and safety of intravenous immunoglobulins (IVIG) combined with rituximab (RTX) (EudraCT 2010-023746-67). Patients with transplant glomerulopathy and anti-HLA donor-specific antibodies (DSA) were eligible. Patients with estimated glomerular filtration rate (eGFR)
metadata.dc.identifier.doi: 10.1111/ajt.14520
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.